(S)-3-Hydroxybutyric acid

CHF 40.00
In stock
AG-CR1-3617-M02525 mgCHF 40.00
AG-CR1-3617-M100100 mgCHF 95.00
More Information
Product Details
Synonyms (S)-β-Hydroxybutyric acid; L-(+)-3-Hydroxybutyric acid; L-(+)-BHB
Product Type Chemical
Properties
Formula C4H8O3
MW 104.1
Merck Index 14: 4816
CAS 6168-83-8
Purity Chemicals ≥98% (TLC)
Appearance White solid.
Solubility Soluble in water, 100% ethanol or methanol.
Identity Determined by 1H-NMR.
Other Product Data Optical Rotation: [α]20/D c=6 in H2O: 25°±1.0°
InChi Key WHBMMWSBFZVSSR-VKHMYHEASA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Physiologically insignificant stereoisomer of (R)-3-Hydroxybutyric acid, a key metabolite of the ketolytic pathway.
  • Anticonvulsant.
  • Endogenous inhibitor of histone deacetylases (HDACs) 1, 3 and 4.
  • Ligand of free fatty acid receptor 3 (FFAR3; GPR41) and hydroxycarboxylic acid receptor 2 (HCAR2; GPR109B).
  • NLRP3 inflammasome inhibitor. Prevents K+-efflux and reduces ASC oligomerization and speck formation.
Product References
  1. Effects of beta-hydroxy butyric acid on insulin binding to its receptor and on autophosphorylation of the receptor: H. Ohtusaka, et al.; Endocrinol. Jpn. 37, 915 (1990)
  2. Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo: J.M. Rho, et al.; Epilepsia 43, 358 (2002)
  3. The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment: M. Vanelli, et al.; Diabetes Nutr. Metab. 16, 312 (2003)
  4. Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis: S.L. Wootton-Gorges, et al.; AJNR 26, 1286 (2005)
  5. β-Hydroxybutyrate activates the NF-κB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes: X. Shi, et al.; Cell. Physiol. Biochem. 33, 920 (2014)
  6. β-hydroxybutyrate: Much more than a metabolite: J. C. Newman & E. Verdin; Diab. Res. Clin. Pract. 106, 173 (2014) (Review)
  7. BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activation: S.P. Fu, et al.; Med. Inflamm. 2014, ID983401 (2014)
  8. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms: S.P. Fu, et al.; J. Neuroinflamm. 12, ID9 (2015)
  9. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease: Y.H. Youm, et al.; Nat. Med. 21, 263 (2015)
  10. Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015)
  11. Inflammasome inhibition: putting out the fire: M.G. Netea & L.A. Joosten; Cell Metab. 21, 513 (2015)
  12. Inflammasome: starving inflammation: E. Kugleberg; Nat. Rev. Immunol. 15, 199 (2015) (Review)
  13. The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.